CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 512 enrolled
Drug / intervention
MP-214 3mg +4 moredrug
Likely dose
MP-214 3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01625000
NCT01625000Phase 3Completed
CompareCT.gov

A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia

Tanabe Pharma Corporation·interventional·Posted Jun 21, 2012·Updated Jan 5, 2026

In Brief

A Phase 3 clinical trial evaluating MP-214 3mg, MP-214 6mg, and 3 other interventions for Schizophrenia. Completed, enrolled 512 participants across 3 sites in 3 countries.

Detailed Summary

The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesJapan, South Korea, Taiwan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 21, 2012
Enrollment StartMay 1, 2012
Primary CompletionAug 1, 2015
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.0 years ago

Interventions

MP-214 3mgdrug

Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.

MP-214 6mgdrug

Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.

MP-214 9mgdrug

Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.

Risperidone 4mgdrug

Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.

Placebodrug

Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.